{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320724045568.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1073/pnas.092327399"}},{"identifier":{"@type":"URI","@value":"https://pnas.org/doi/pdf/10.1073/pnas.092327399"}}],"dc:title":[{"@value":"Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>\n            The ATP-binding cassette transporter 1 (ABCA1) has recently been identified as a key regulator of high-density lipoprotein (HDL) metabolism, which is defective in familial HDL-deficiency syndromes such as Tangier disease. ABCA1 functions as a facilitator of cellular cholesterol and phospholipid efflux, and its expression is induced during cholesterol uptake in macrophages. To assess the role of macrophage ABCA1 in atherosclerosis, we generated low-density lipoprotein (LDL) receptor knockout (LDLr\n            <jats:sup>−/−</jats:sup>\n            ) mice that are selectively deficient in leukocyte ABCA1 (ABCA1\n            <jats:sup>−/−</jats:sup>\n            ) by using bone marrow transfer (ABCA1\n            <jats:sup>−/−</jats:sup>\n            → LDLr\n            <jats:sup>−/−</jats:sup>\n            ). Here we demonstrate that ABCA1\n            <jats:sup>−/−</jats:sup>\n            → LDLr\n            <jats:sup>−/−</jats:sup>\n            chimeras develop significantly larger and more advanced atherosclerotic lesions compared with chimeric LDLr\n            <jats:sup>−/−</jats:sup>\n            mice with functional ABCA1 in hematopoietic cells. Targeted disruption of leukocyte ABCA1 function did not affect plasma HDL cholesterol levels. The amount of macrophages in liver and spleen and peripheral blood leukocyte counts is increased in the ABCA1\n            <jats:sup>−/−</jats:sup>\n            → LDLr\n            <jats:sup>−/−</jats:sup>\n            chimeras. Our results provide evidence that leukocyte ABCA1 plays a critical role in the protection against atherosclerosis, and we identify ABCA1 as a leukocyte factor that controls the recruitment of inflammatory cells.\n          </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380861294927156484","@type":"Researcher","foaf:name":[{"@value":"Miranda Van Eck"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156609","@type":"Researcher","foaf:name":[{"@value":"I. Sophie T. Bos"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156612","@type":"Researcher","foaf:name":[{"@value":"Wolfgang E. Kaminski"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156482","@type":"Researcher","foaf:name":[{"@value":"Evelyn Orsó"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156610","@type":"Researcher","foaf:name":[{"@value":"Gregor Rothe"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156483","@type":"Researcher","foaf:name":[{"@value":"Jaap Twisk"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156486","@type":"Researcher","foaf:name":[{"@value":"Alfred Böttcher"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156480","@type":"Researcher","foaf:name":[{"@value":"Edwin S. Van Amersfoort"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156611","@type":"Researcher","foaf:name":[{"@value":"Trudy A. Christiansen-Weber"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156485","@type":"Researcher","foaf:name":[{"@value":"Wai-Ping Fung-Leung"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156608","@type":"Researcher","foaf:name":[{"@value":"Theo J. C. Van Berkel"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861294927156481","@type":"Researcher","foaf:name":[{"@value":"Gerd Schmitz"}],"jpcoar:affiliationName":[{"@value":"Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Sylvius Laboratories, Leiden University, P.O. Box 9503, 2300 RA Leiden, The Netherlands; Institute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, D-93042 Regensburg, Germany; and R. W. Johnson Pharmaceutical Research Institute, San Diego, CA 92121"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00278424"},{"@type":"EISSN","@value":"10916490"}],"prism:publicationName":[{"@value":"Proceedings of the National Academy of Sciences"}],"dc:publisher":[{"@value":"Proceedings of the National Academy of Sciences"}],"prism:publicationDate":"2002-04-23","prism:volume":"99","prism:number":"9","prism:startingPage":"6298","prism:endingPage":"6303"},"reviewed":"false","url":[{"@id":"https://pnas.org/doi/pdf/10.1073/pnas.092327399"}],"createdAt":"2002-07-26","modifiedAt":"2022-04-12","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022708918516992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"FTY720 Reduces Lipid Accumulation by Upregulating ABCA1 through Liver X Receptor and Sphingosine Kinase 2 Signaling in Macrophages"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231952857344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Chitinase Inhibition Promotes Atherosclerosis in Hyperlipidemic Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693708275584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE\n            <sup>−/−</sup>\n            Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285708096265472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"LXR Agonism Upregulates the Macrophage ABCA1/Syntrophin Protein Complex That Can Bind ApoA-I and Stabilized ABCA1 Protein, but Complex Loss Does Not Inhibit Lipid Efflux"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814743352320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-activated receptor α and fundamentally changing lipid metabolism"}]},{"@id":"https://cir.nii.ac.jp/crid/1362257541911988864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening of House Dust from Chinese Homes for Chemicals with Liver X Receptors Binding Activities and Characterization of Atherosclerotic Activity Using an\n                    <i>in Vitro</i>\n                    Macrophage Cell Line and ApoE−/− Mice"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1073/pnas.092327399"},{"@type":"CROSSREF","@value":"10.1161/jaha.112.003376_references_DOI_OPa8MIZ0RDjwPXuglttlFRvqiqc"},{"@type":"CROSSREF","@value":"10.1021/acs.biochem.5b00894_references_DOI_OPa8MIZ0RDjwPXuglttlFRvqiqc"},{"@type":"CROSSREF","@value":"10.3390/ijms232314617_references_DOI_OPa8MIZ0RDjwPXuglttlFRvqiqc"},{"@type":"CROSSREF","@value":"10.1093/cvr/cvad082_references_DOI_OPa8MIZ0RDjwPXuglttlFRvqiqc"},{"@type":"CROSSREF","@value":"10.1289/ehp5039_references_DOI_OPa8MIZ0RDjwPXuglttlFRvqiqc"},{"@type":"CROSSREF","@value":"10.1016/j.ajpath.2013.04.003_references_DOI_OPa8MIZ0RDjwPXuglttlFRvqiqc"}]}